Hypogammaglobulinaemia after rituximab treatment--incidence and outcomes
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hypogammaglobulinaemia after rituximab treatment--incidence and outcomes
Authors
Keywords
-
Journal
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
Volume 107, Issue 10, Pages 821-828
Publisher
Oxford University Press (OUP)
Online
2014-04-29
DOI
10.1093/qjmed/hcu094
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia
- (2013) Su W. Maung et al. BRITISH JOURNAL OF HAEMATOLOGY
- Management of secondary immune deficiencies
- (2013) Luc Mouthon et al. Current Opinion in Allergy and Clinical Immunology
- Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis
- (2013) B Duxbury et al. LUPUS
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
- (2012) D E Furst et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
- (2012) Ronald F van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections
- (2012) Carla Casulo et al. Clinical Lymphoma Myeloma & Leukemia
- Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics
- (2012) Inmaculada De La Torre et al. RHEUMATOLOGY
- Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
- (2011) Simone Lanini et al. BMC Medicine
- Acycloguanosine for the treatment of aplastic anaemia
- (2010) Pietro Leoni et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Does rituximab increase the incidence of infectious complications? A narrative review
- (2010) Theodoros Kelesidis et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
- (2010) Tadeusz Robak et al. JOURNAL OF CLINICAL ONCOLOGY
- Does rituximab aggravate pre-existing hypogammaglobulinaemia?
- (2010) L. Diwakar et al. JOURNAL OF CLINICAL PATHOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Late-Onset Neutropenia After Rituximab Treatment
- (2010) Ofir Wolach et al. MEDICINE
- Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial
- (2009) Clifton O. Bingham et al. ARTHRITIS AND RHEUMATISM
- Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab
- (2009) Sander van Assen et al. ARTHRITIS AND RHEUMATISM
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
- (2009) K. R. Carson et al. BLOOD
- Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials
- (2009) Liat Vidal et al. JNCI-Journal of the National Cancer Institute
- Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis
- (2009) Sercan Aksoy et al. LEUKEMIA & LYMPHOMA
- Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma
- (2008) L K Hicks et al. BONE MARROW TRANSPLANTATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now